Abstract：Objective To construct the recombinant adenoviral vector carrying the rat interleukin-10 (rIL-10) gene, and to investigate whether it is stably expressed in bone marrow mesenchymal stem cells. Methods The rIL-10 gene was amplified by PCR from template rIL-10 cDNA, and the recovered 656 bp rIL-10 DNA fragment was cloned into pcDNA3.1 to construct pcDNA3.1-IL-10. Then HEK293 cells were transfected with pcDNA3.1-IL-10 and adenoviral vector for homologous recombination, and sequencing and PCR were used to evaluate whether recombination was successful. HEK293 cells were lysed by repeated freeze-thaw cycles, and bone marrow mesenchymal stem cells were infected with the virus solution containing the rIL-10 gene. Western blot was used to measure the expression of rIL-10 in bone marrow mesenchymal stem cells. Results Sequencing and PCR verified that the rIL-10 adenoviral vector was successfully constructed, with a virus titer of 4×109 PFU/mL. The expression of IL-10 was detected after bone marrow mesenchymal stem cells were infected by the virus solution containing the rIL-10 gene. Conclusions The constructed rIL-10 recombinant adenovirus can mediate the stable expression of rIL-10 gene in bone marrow mesenchymal stem cells, which provides a basis for gene transplantation therapy of inflammatory bowel disease.
ZHANG Wen-Ting,TANG Juan,ZHAO Hong-Mei et al. Construction of rat interleukin-10 adenoviral vector and its expression in bone marrow mesenchymal stem cells[J]. CJCP, 2019, 21(7): 708-712.
Miheller P, Lakatos PL, Horváth G, et al. Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe-a Hungarian nationwide observational study[J]. BMC Gastroenterol, 2009, 9:66.
[2]
Shouval DS, Biswas A, Goettel JA, et al. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function[J]. Immunity, 2014, 40(5):706-719.
[3]
Christodoulou K, Wiskin AE, Gibson J, et al. Next generation exome sequencing of paediatric inflammatory bowel disease patients identifies rare and novel variants in candidate genes[J]. Gut, 2013, 62(7):977-984.
[4]
Shim JO, Seo JK. Very early-onset inflammatory bowel disease (IBD) in infancy is a different disease entity from adult-onset IBD; one form of interleukin-10 receptor mutations[J]. J Hum Genet, 2014, 59(6):337-341.
[5]
Lin Z, Wang Z, Hegarty JP, et al. Genetic association and epistatic interaction of the interleukin-10 signaling pathway in pediatric inflammatory bowel disease[J]. World J Gastroenterol, 2017, 23(27):4897-4909.
Shim JO, Hwang S, Yang HR, et al. Interleukin-10 receptor mutations in children with neonatal-onset Crohn's disease and intractable ulcerating enterocolitis[J]. Eur J Gastroenterol Hepatol, 2013, 25(10):1235-1240.
[8]
Doecke JD, Simms LA, Zhao ZZ, et al. Genetic susceptibility in IBD:overlap between ulcerative colitis and Crohn's disease[J]. Inflamm Bowel Dis, 2013, 19(2):240-245.
[9]
Arthur A, Zannettino A, Gronthos S. The therapeutic applications of multipotential mesenchymal/stromal stem cells in skeletal tissue repair[J]. J Cell Physiol, 2009, 218(2):237-245.
[10]
Sémont A, Mouiseddine M, François A, et al. Mesenchymal stem cells improve small intestinal integrity through regulation of endogenous epithelial cell homeostasis[J]. Cell Death Differ, 2010, 17(6):952-961.
[11]
Chen QQ, Yan L, Wang CZ, et al. Mesenchymal stem cells alleviate TNBS-induced colitis by modulating inflammatory and autoimmune responses[J]. World J Gastroenterol, 2013, 19(29):4702-4717.
[12]
He XW, He XS, Lian L, et al. Systemic infusion of bone marrow-derived mesenchymal stem cells for treatment of experimental colitis in mice[J]. Dig Dis Sci, 2012, 57(12):3136-3144.
[13]
Qi Y, Jiang D, Sindrilaru A, et al. TSG-6 released from intradermally injected mesenchymal stem cells accelerates wound healing and reduces tissue fibrosis in murine full-thickness skin wounds[J]. J Invest Dermatol, 2014, 134(2):526-537.
[14]
Yang J, Liu XX, Fan H, et al. Extracellular vesicles derived from bone marrow mesenchymal stem cells protect against experimental colitis via attenuating colon inflammation, oxidative stress and apoptosis[J]. PLoS One, 2015, 10(10):e0140551.
[15]
Anderson P, Souza-Moreira L, Morell M, et al. Adipose-derived mesenchymal stromal cells induce immunomodulatory macrophages which protect from experimental colitis and sepsis[J]. Gut, 2013, 62(8):1131-1141.
[16]
Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD[J]. Am J Gastroenterol, 2011, 106(4):685-698.
[17]
Schreiber S, Heinig T, Thiele HG, et al. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease[J]. Gastroenterology, 1995, 108(5):1434-1444.
[18]
Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor[J]. Annu Rev Immunol, 2001, 19:683-765.
[19]
Tilg H, van Montfrans C, van den Ende A, et al. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma[J]. Gut, 2002, 50(2):191-195.
[20]
Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10[J]. Science, 2000, 289(5483):1352-1355.
[21]
Dave M, Mehta K, Luther J, et al. Mesenchymal stem cell therapy for inflammatory bowel disease:a systematic review and meta-analysis[J]. Inflamm Bowel Dis, 2015, 21(11):2696-2707.
[22]
Niu GC, Liu L, Zheng L, et al. Mesenchymal stem cell transplantation improves chronic colitis-associated complications through inhibiting the activity of toll-like receptor-4 in mice[J]. BMC Gastroenterol, 2018, 18(1):127.
